CTI: Pacritinib Is Sole Product Candidate in Active Development
CTI: Pacritinib Is Sole Product Candidate in Active Development
*DJ CTI BioPharma Corp. Looks to Raise $50.7 Million via Stock Offer
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:53 ET (03:53 GMT)
*DJ CTI Offering 14,260,800 Shares of Common Stock, 600 Shares of Series X(1) Preferred Stock
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:54 ET (03:54 GMT)
*DJ CTI Common Stock Priced at $2.50 Each, Preferred Stock Priced at $25,000
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:55 ET (03:55 GMT)
*DJ CTI: Each Preferred Share Will Be Convertible Into 10,000 Common Shares
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:55 ET (03:55 GMT)
*DJ CTI Has Granted Underwriters Option for Additional 2,139,120 Common Shares
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:56 ET (03:56 GMT)
*DJ CTI Offering Is Expected to Close on or About April 6
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:56 ET (03:56 GMT)
*DJ CTI Intends to Use Proceeds for Commercialization Activities for Pacritinib
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:57 ET (03:57 GMT)
*DJ CTI: Pacritinib Is Sole Product Candidate in Active Development
(MORE TO FOLLOW) Dow Jones Newswires
March 31, 2021 23:58 ET (03:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
*DJ CTI BioPharma Corp. Looks to Raise $50.7 Million via Stock Offer
*DJ CTI BioPharma Corp.希望通過股票發售籌集5070萬美元
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:53 ET (03:53 GMT)
2021年3月31日美國東部時間23：53(格林尼治標準時間03：53)
*DJ CTI Offering 14,260,800 Shares of Common Stock, 600 Shares of Series X(1) Preferred Stock
*DJ CTI發售14,260,800股普通股，600股X(1)系列優先股
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:54 ET (03:54 GMT)
2021年3月31日美國東部時間23：54(格林尼治標準時間03：54)
*DJ CTI Common Stock Priced at $2.50 Each, Preferred Stock Priced at $25,000
*DJ CTI普通股定價為每股2.50美元，優先股定價為25,000美元
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:55 ET (03:55 GMT)
2021年3月31日美國東部時間23：55(格林尼治標準時間03：55)
*DJ CTI: Each Preferred Share Will Be Convertible Into 10,000 Common Shares
*DJ CTI：每股優先股將可轉換為10,000股普通股
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:55 ET (03:55 GMT)
2021年3月31日美國東部時間23：55(格林尼治標準時間03：55)
*DJ CTI Has Granted Underwriters Option for Additional 2,139,120 Common Shares
*DJ CTI已授予承銷商額外2,139,120股普通股的選擇權
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:56 ET (03:56 GMT)
2021年3月31日美國東部時間23：56(格林尼治標準時間03：56)
*DJ CTI Offering Is Expected to Close on or About April 6
*DJ CTI產品預計將於4月6日左右結束
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:56 ET (03:56 GMT)
2021年3月31日美國東部時間23：56(格林尼治標準時間03：56)
*DJ CTI Intends to Use Proceeds for Commercialization Activities for Pacritinib
*DJ CTI打算將收益用於Pacritinib的商業化活動
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:57 ET (03:57 GMT)
2021年3月31日美國東部時間23：57(格林尼治標準時間03：57)
*DJ CTI: Pacritinib Is Sole Product Candidate in Active Development
*DJ CTI：帕利替尼是積極開發的唯一候選產品
(MORE TO FOLLOW) Dow Jones Newswires
(更多後續報道)道瓊斯通訊社
March 31, 2021 23:58 ET (03:58 GMT)
2021年3月31日美國東部時間23：58(格林尼治標準時間03：58)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧